Form 4: Alto Neuroscience Director Dreyfus Acquires Stock Options

Director Andrew Dreyfus acquired stock options for 15,287 shares of Alto Neuroscience, Inc. on May 13, 2025, as part of the company's Non-Employee Director Compensation Policy.

Summary

• Andrew Dreyfus, a director of Alto Neuroscience, Inc., acquired stock options to purchase 15,287 shares of common stock on May 13, 2025.
• The exercise price of the options is $2.37 per share.
• The options vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next Annual Meeting following the grant date, contingent upon continuous service.
• The options expire on May 12, 2035.
• The grant was made under the Issuer's Non-Employee Director Compensation Policy, and no consideration was paid by Dreyfus for the options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice, aligning director interests with shareholders. There are no red flags or negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

Not applicable.

Industry Context

This is a standard practice for compensating non-employee directors in publicly traded companies, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice among publicly traded companies to align their interests with those of shareholders.
• The vesting schedule of one year or the next annual meeting is also a typical arrangement.
• Comparable companies in the biotechnology sector, such as Biogen or Amgen, often use similar equity-based compensation plans for their directors.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, director compensation, Form 4, ANRO, Alto Neuroscience, Dreyfus, insider transaction